The Challenging Anticoagulant Therapy in Patient with COVID-19-Associated Coagulopathy

Raissa Virgy Rianda, Mohammad Subkhan, Aditya Doni Pradana, Fahrun Nisa’i Fatimah, Rama Azalix Rianda, Muhammad Perdana Airlangga, Muhammad Miftahussurur


COVID-19 became a widespread infectious disease in late 2019. Indonesia currently has the highest COVID-19 mortality rate in Asia, between 4-5 percent. Interestingly, COVID-19-associated coagulopathy characterized by an increase of several procoagulant factor levels, including fibrinogen and D-dimer, that has been associated with higher mortality and unfavorable outcomes. We report a case of a 30-year-old male admitted to the hospital with a profuse vomiting and worsening fever, cough and shortness of breath, and was diagnosed with COVID-19-associated coagulopathy. Seven days after admission, he became deteriorated with significant reduction of oxygen saturation and his coagulation parameter levels were increased with highly suspicion of pulmonary embolism. He was treated with azithromycin, isoprinosine, lopinavir, and fondaparinux with thromboprophylaxis dosage since admission. The role of increased fondaparinux dosage at the time of clinical deterioration was then followed by clinical improvement and reduced D-dimer level. Anticoagulant therapy, mainly with fondaparinux, showed a better prognosis in patients with markedly elevated D-Dimer. Fondaparinux needs to be monitored appropriately to prevent bleeding and adverse. The patient was discharged from the hospital in an improved condition and normal D-Dimer levels. There were no bleeding event nor other major side effects that had been found. The decision for increasing dose of anticoagulant may be determined on individual basis, considering risks, benefits, and also the most important is clinical findings.


COVID-19; Coagulopathy; Fondaparinux; Anticoagulation; Thrombosis


Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.

WHO. Coronavirus disease situation report. World Health Organization. vol. 19. 2020.

Lippi G. D-dimer is associated with severity of Coronavirus disease 2019: A pooled D-dimer is associated with severity of Coronavirus disease 2019: A pooled analysis. 2020:2019–21.

Fogarty H, Townsend L, Ni Cheallaigh C, et al. COVID19 coagulopathy in Caucasian patients. Br J Haematol. 2020.

Adhikari SP, Meng S, Wu Y, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. 2020:1–12.

Mezalek ZT, Khibri H, Ammouri W, et al. COVID-19 associated coagulopathy and thrombotic complications 2020.

Ozma MA, Maroufi P, Khodadadi E. Clinical manifestation, diagnosis, prevention and control of SARS-CoV-2 (COVID-19) during the outbreak period 2020;2.

Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46:1089–98.

Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020:1094–9.

McGonagle D, O’Donnell JS, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2020;2019:1–9.

García LF. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol. 2020;11:4–8.

Suresh M V, Balijepalli S, Zhang B, et al. Hypoxia-inducible factor (HIF)-1α promotes inflammation and injury following aspiration-induced lung injury in mice. Shock. 2019;52.

Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844–7.

Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020:1023–6.

Turpie AGG. Selective factor Xa inhibition with fondaparinux: From concept to clinical benefit. Eur Hear Journal. 2008;10 (Suppl):1–7.

Bjorvatn A, Kristiansen F. Fondaparinux sodium compared with enoxaparin sodium: a cost-effectiveness analysis. Am J Cardiovasc Drugs. 2005;5:121–30.

Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002;162:1833–40.

British Thoracic Society. BTS Guidance on Venous Thromboembolic Disease in patients with COVID-19. Br Thorac Soc. 2020;2:7.

Ramacciotti E, Macedo AS, Biagioni RB, et al. Evidence-based practical guidance for the antithrombotic management in patients with Coronavirus disease (COVID-19) in 2020. Clin Appl Thromb. 2020;26.

AlHajri L, Gebran N. The use of low molecular weight heparin for venous thromboembolism prophylaxis in medical patients: How much are we adherent to the guidelines? Open J Intern Med. 2015;5:81–91.

Bi X, Su Z, Yan H, et al. Prediction of severe illness due to COVID-19 based on an analysis of initial fibrinogen to albumin ratio and platelet count prediction of severe illness due to COVID-19 based on an analysis of initial fibrinogen to albumin ratio and platelet count. Platelets. 2020;31:674–9.

Wang J, Hajizadeh N, Moore EE, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series 2020:1–4.

Full Text: PDF


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.